Bioactive Research

Bioactive conducts a biotech focussed, multi-disciplinary, research and development program.

<< Note to Practitioners: please page down to section titled: ‘Scientific Study Comparisons’ >>

Discovered findings…

Thus far Bioactive have discovered novel and diverse findings in the areas of Human Health, Veterinary Science and Agricultural Biology.

These findings lay within the following areas(1a):

  • Human health care relating to specific aspects of infectious diseases and digestive, skin & joint related inflammatory conditions;
  • Veterinary Science and Agricultural biology relating to specific aspects of livestock feed supplements that, among other discovered characteristics, control intestinal parasite levels and greenhouse gas emissions.  

Extract research & QC lab 01

 Filed patent…

Bioactive researchers have a patent filed under ‘A herbal composition of an enriched extract… for the treatment or prevention of inflammation’.

The key to this patented extract is the inbuilt stability of it’s anti-oxidant rich base(1). This product-ready extract allows consistent efficacy with acceptable OTC shelf-life allowing for a variety of applications and products.

Click on Products to see the Drug Development Pipeline & Traditional Medicine suite of products that have resulted from the Bioactive research and development program.

OTC: Over The Counter

 Agri-research

Bioactive, over a number of years, have developed a proprietary harvest method for it’s Certified Organic plantation. In a world first, Bioactive now have the ability to sustainably harvest their key plant species without the need to replant.

The importance of this discovery is that extract volumes are dependant on the plant’s size and age. In the case of Bioactive they now have a 20 year head start on the market with a sustainable supply of raw material.

Proprietary Bark Harvester


Inflammatory Bowel Disease (IBD) refers to conditions such as ulcerative colitis and Crohn’s disease that are characterized by chronic inflammation of the intestine suggesting that the Bioactive anti-inflammatory platform may offer an effective treatment for IBD.

IBD patients are currently managed during short-term episodes through the use of anti-inflammatory medications, or immunosuppressants such as corticosteroids. These provide symptomatic relief over short periods of time, but do not deliver a cure. These non-specific drugs all act by a generalized suppression of the immune response, with the unfortunate side effect of increasing the patient’s susceptibility to infection.

Bioactive’s early discovered plant extract formula, Khapre®, and future targeted drug candidate, Khapreze®, are designed to specifically quiet the inflammatory response associated with IBD but does not induce a generalized immune suppression. Studies show that ingredients in Khapre® display immunostimulating principals(2).

Approximately one million people in the United States suffer from IBD. In recent years the total treatment market exceeded 1.5 billion dollars.

 


What’s in the pipeline?

Anti-microbial properties discovered: Traditional medicine also reports that Bioactive researched plant material can help to stop the effects of mucosal diarrhoea signifying a powerful antimicrobial action towards bacterial infection of the Gastro-Intestinal tract(3).

More recent research has revealed significant antibacterial and notably MRSA activities using Bioactive researched plant material against methicillin resistant strains of Staphyloccocus aureus(4).

Bioactive Laboratories is continuing scientific research in these and other areas with research collaborators including the Walter and Eliza Hall Institute for Medical Research, Griffith University, Southern Cross University and the University of Western Australia. The company is focused towards developing more targeted anti-inflammatory and anti-microbial pharmaceutical products. Click on Drug Development Pipeline to learn more.


Disclaimer: Please note that any statements aligned to product descriptions on this website and the products themselves are in varying stages of evaluation by the Therapeutic Goods Administration in Australia (TGA), the Food and Drug Administration in the United States of America (FDA) & the Australian Pesticides and Veterinary Medicines Authority (APVMA). These products are not intended to diagnose, treat, cure or prevent any disease.

Bioactive recommend a balanced diet with plenty of fresh filtered water and regular daily exercise.


(1a) Partners have access to web source references and scientific studies – contact us to find out more

 

 


 Scientific Study Comparisons:

Chart - anti-inflammatory

(click on the chart to make it bigger)

A)     KSBE (Khaya Senegalensis Bark Extract) vs COX-2 Inhibition Study; Eurofins Panlabs, Study Code: AB16492, Compound Code: BA201; for Bioactive Solutions Pty Ltd, Dr Maud Eijkenboom (Research Consultant), received 30th Oct 2012

B)     KSBE vs Voltaren; Carrageenan-induced rat paw edema Study; KSBE 150mg/kg compared to 20mg/kg diclofenac sodium (Australian trade name: Voltaren). Kolawole OT, Akiibinu MO, Ayankunle AA and Awe EO., 2013. Evaluation of Anti-inflammatory and Antinociceptive Potentials of Khaya senegalensis A. Juss (Meliaceae) Stem Bark Aqueous Extract. British Journal of Medicine & Medical Research, 3(2): para2.3.1,pp218 & table 1. pp222, published 19th Jan 2013

C)     KSBE vs Indocid; Hypotonicity-induced Hemolysis Study on Human Blood cells; KSBE 500µg/ml compared to 100µg/ml Indomethacin (Australian trade name: Indocid). Kolawole OT, Akiibinu MO, Ayankunle AA and Awe EO., 2013. Evaluation of Anti-inflammatory and Antinociceptive Potentials of Khaya senegalensis A. Juss (Meliaceae) Stem Bark Aqueous Extract. British Journal of Medicine & Medical Research, 3(2): para2.3.7,pp220 & tables 5 & 6. pp223, published 19th Jan 2013

D)     KSBE vs Hydrocortisone; Cotton pellet-induced Granuloma in Rats Study; KSBE 150mg/kg compared to 15mg/kg Hydrocortisone. Kolawole OT, Akiibinu MO, Ayankunle AA and Awe EO., 2013. Evaluation of Anti-inflammatory and Antinociceptive Potentials of Khaya senegalensis A. Juss (Meliaceae) Stem Bark Aqueous Extract. British Journal of Medicine & Medical Research, 3(2): para2.3.3,pp219 & table 3. pp223, published 19th Jan 2013

 


Chart - anti-oxidant

(click on the chart to make it bigger)

(1)    KSLE (Khaya Senegalensis Leaf Extract – material source: the Bioactive Certified Organic plantation); [Antioxidant Free Radical Scavenger Activity 96%], ABTS Radical Study; Eurofins Panlabs, Study Code: AB16492, Compound Code: BA101; for Bioactive Solutions Pty Ltd, Dr Maud Eijkenboom (Research Consultant), received 30th Oct 2012

(2)    KSBE (Khaya Senegalensis Bark Extract – material source: the Bioactive Certified Organic plantation); [Antioxidant Free Radical Scavenger Activity 95%],ABTS Radical Study; Eurofins Panlabs, Study Code: AB16492, Compound Code: BA201; for Bioactive Solutions Pty Ltd, Dr Maud Eijkenboom (Research Consultant), received 30th Oct 2012

(3)    KSBE vs BHT (Butylated hydroxytoluene); [BHT is a synthetic antioxidant used as a common food preservative. In Europe it is used under additive code E321.] [Antioxidant
Free Radical Scavenger Activity 90%]
, DPPS Radical Study; Androulakis XM, Muga SJ, Chen F, Koita Y, Toure B, Wargovich MJ, 2006. Chemopreventive Effects of Khaya Senegalensis Bark Extract on Human Colorectal Cancer. Anticancer Research, 26: 2397-2406 (2006): fig 4A. pp2402 at 4µg/µl concentration, accepted 15th Mar 2006

(4)    KSBE vs Catechin; [Catechin is a naturally occurring antioxidant commonly found in substances such as green tea.] [Antioxidant Free Radical Scavenger Activity 82.5%],DPPS Radical Study; Kolawole OT, Akiibinu MO, Ayankunle AA and Awe EO., 2013. Evaluation of Anti-inflammatory and Antinociceptive Potentials of Khaya senegalensis A. Juss (Meliaceae) Stem Bark Aqueous Extract. British Journal of Medicine & Medical Research, 3(2): fig 2. pp224, published 19th Jan 2013

 


Chart - liver de-tox

 (click on the chart to make it bigger)

(1)    KSBE (Khaya Senegalensis Bark Extract) vs AST (Aspartate transaminase) Study; [AST is a key hepatotoxin enzyme marker; High levels of AST can indicate liver damage; Inhibitory increase 57.3% based on calculation source: control level (A)paracetamol only=59.12IU, (B)KSBE+paracetamol=25.25IU, (A)-(B)=(C), (C)/(A)X100=inhibitory increase percentage]  – source: Ojo OO, Nadro MS, Tella IO, 2006. Protection of rats by extracts of some common Nigerian trees against acetaminophen-induced hepatotoxicity. African Journal of Biotechnology Vol 5 (9), pp 755-760, 2 May 2006

(2)    KSBE (Khaya Senegalensis Bark Extract) vs ALT (Alanine aminotransferase) Study; [ALT is a key hepatotoxin enzyme marker; High levels of ALT can indicate liver damage; Inhibitory increase 56.7% based on calculation source: control level (A)paracetamol only=87.17IU, (B)KSBE+paracetamol=37.75IU, (A)-(B)=(C), (C)/(A )X100=inhibitory increase percentage]  – source: Ojo OO, Nadro MS, Tella IO, 2006. Protection of rats by extracts of some common Nigerian trees against acetaminophen-induced hepatotoxicity. African Journal of Biotechnology Vol 5 (9), pp 755-760, 2 May 2006

(3)    KSBE (Khaya Senegalensis Bark Extract) vs ALP (Alkaline phosphatase) Study; [ALP is a key hepatotoxin enzyme marker; High levels of ALP can indicate liver damage; Inhibitory increase 34.6% based on calculation source: control level (A)paracetamol only=150.62KA/unit, (B)KSBE+paracetamol=98.56KA/unit, (A)-(B)=(C), (C)/(A)X100=inhibitory increase percentage]  – source: Ojo OO, Nadro MS, Tella IO, 2006. Protection of rats by extracts of some common Nigerian trees against acetaminophen-induced hepatotoxicity. African Journal of Biotechnology Vol 5 (9), pp 755-760, 2 May 2006


Chart - anti-cancer

(click on the chart to make it bigger)

(1)    KSBE (Khaya Senegalensis Bark Extract) vs Caspase-3 (Key Oncology marker) Study; [Activity increase 97% – on source: Human recombinant E. Coli cells]; Eurofins Panlabs, Study Code: AB16492, Compound Code: BA201; for Bioactive Solutions Pty Ltd, Dr Maud Eijkenboom (Research Consultant), received 30th Oct 2012

(2)    KSBE vs Caspase-3 [HCA-7] Study; [Activity increase 97% – on source: Human Colon Cancer cells HCA-7]; Androulakis XM, Muga SJ, Chen F, Koita Y, Toure B, Wargovich MJ, 2006.  Chemopreventive Effects of Khaya Senegalensis Bark Extract on Human Colorectal Cancer. Anticancer Research, 26: 2397-2406 (2006): pp2400 & fig 6. pp2404, accepted 15th Mar 2006

(3)    KSBE vs Caspase-3 [HCT-15] Study; [Activity increase 59% – on source: Human Colon Cancer cells HCT-15]; Androulakis XM, Muga SJ, Chen F, Koita Y, Toure B, Wargovich MJ, 2006.  Chemopreventive Effects of Khaya Senegalensis Bark Extract on Human Colorectal Cancer. Anticancer Research, 26: 2397-2406 (2006): pp2400 & fig 6. pp2404, accepted 15th Mar 2006

(4)    KSBE vs Caspase-3 [HT-29] Study; [Activity increase 27% – on source: Human Colon Cancer cells HT-29]; Androulakis XM, Muga SJ, Chen F, Koita Y, Toure B, Wargovich MJ, 2006.  Chemopreventive Effects of Khaya Senegalensis Bark Extract on Human Colorectal Cancer. Anticancer Research, 26: 2397-2406 (2006): pp2400 & fig 6. pp2404, accepted 15th Mar 2006

 

 

 


Page references:

(1) See Anti-oxidant chart & references above.

(2) Source: Amastigote forms of Leishmania parasite in the macrophages only. The significant by-product was the discovery of immunostimulating principals whereby the Leishmania promastigotes were in turn unaffected. Source: Kayser O, Abreu PM., Antileishmania and Immunostimulating Activities of Two Dimeric Proanthocyanidins From Khaya senegalensis; Pharmaceutical Biology, 2001, Vol. 39, No. 4, pp. 284–288

(3) Source: PROTA database 2012

(4)  Source: